This review describes and commentates on recent advances in the understanding of dengue pathogenesis and immunity, plus clinical research on vaccines and therapeutics. We expand specifically on the role of the dermis in dengue virus infection, the contribution of cellular and humoral immune responses to pathogenesis and immunity, NS1 and mechanisms of virus immune evasion. Additionally we review a series of therapeutic intervention trials for dengue, as well as recent clinical research aimed at improving clinical diagnosis, risk prediction and disease classification.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2015.09.103 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Human migrations, anthropogenic changes, and insect-borne diseases in Latin America.
Parasit Vectors
January 2025
Department of Agriculture, Food and Environment, University of Pisa, Pisa, Italy.
Rapid urbanization and migration in Latin America have intensified exposure to insect-borne diseases. Malaria, Chagas disease, yellow fever, and leishmaniasis have historically afflicted the region, while dengue, chikungunya, and Zika have been described and expanded more recently. The increased presence of synanthropic vector species and spread into previously unaffected areas due to urbanization and climate warming have intensified pathogen transmission risks.
View Article and Find Full Text PDFSpatiotemporal analysis of mosquito-borne infections and mosquito vectors in mainland Portugal.
BMC Infect Dis
January 2025
EPIUnit - Instituto de Saúde Pública, Universidade do Porto, Rua das Taipas, nº 135, Porto, 4050 - 600, Portugal.
Background: The incidence of mosquito-borne infections has increased worldwide. Mainland Portugal's characteristics might favour the (re)emergence of mosquito-borne diseases. This study aimed to characterize the spatial distribution of vectors and notification rates of imported cases of mosquito-borne infections in mainland Portugal and demarcate the areas where these geographies overlap.
View Article and Find Full Text PDFNeutralization of omicron subvariants and antigenic cartography following multiple COVID 19 vaccinations and repeated omicron non JN.1 or JN.1 infections.
Sci Rep
January 2025
Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.
The ongoing emergence of SARS-CoV-2 variants, combined with antigen exposures from different waves and vaccinations, poses challenges in updating COVID-19 vaccine antigens. We collected 206 sera from individuals with vaccination-only, hybrid immunity, and single or repeated omicron post-vaccination infections (PVIs), including non-JN.1 and JN.
View Article and Find Full Text PDFZika and Dengue Virus Autoimmunity: An Overview of Related Disorders and Their Potential Mechanisms.
Rev Med Virol
January 2025
Department of Critical Care Medicine, Affiliated Hospital of Jiangnan University, Wuxi, China.
Zika virus (ZIKV) and dengue virus (DENV) are two major mosquito-borne flaviviruses that pose a significant threat to the global public health system, particularly in tropical regions. The clinical outcomes related to these viral pathogens can vary from self-limiting asymptomatic infections to various forms of life-threatening pathological conditions such as haemorrhagic disorders. In addition to the direct effects of the viral pathogens, immune processes play also a significant function in the development of diseases mediated by ZIKV and DENV.
View Article and Find Full Text PDFDevelopment and optimization of an mRNA-vectored single-chain IgA1 isotype monoclonal antibody with potential to treat or prevent dengue virus infection.
Antiviral Res
January 2025
Department of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA; Institute for Global Health and Translational Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210, USA. Electronic address:
Dengue virus (DENV) is a rapidly expanding infectious disease threat that causes an estimated 100 million symptomatic infections every year. A barrier to preventing DENV infections with traditional vaccines or prophylactic monoclonal antibody (mAb) therapies is the phenomenon of Antibody-Dependent Enhancement (ADE), wherein sub-neutralizing levels of DENV-specific IgG antibodies can enhance infection and pathogenesis rather than providing protection from disease. Fortunately, IgG is not the only antibody isotype capable of binding and neutralizing DENV, as DENV-specific IgA1 isotype mAbs can bind and neutralize DENV while without exhibiting any ADE activity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!